Assess whether RWE can replace or only supplement an RCT from RWE protocol

Situation

In a mid-size sponsor after a complete response letter, RWE protocol that may not meet regulator expectations is the evidence after a payer demanding RWE the protocol cannot generate. Regulatory-affairs lead has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences FDA Response and Labeling close using RWE protocol that may not meet regulator expectations.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose RWE can replace / Only supplement an RCT using RWE protocol that may not meet regulator expectations after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• Authorize RWE can replace now; RWE protocol that may not meet regulator expectations already has the discriminator after a payer demanding RWE the protocol cannot generate.
• Keep Only supplement an RCT in force until RWE protocol that may not meet regulator expectations is completed after a payer demanding RWE the protocol cannot generate for regulatory-affairs lead.
• Treat RWE protocol that may not meet regulator expectations as RWE can replace because both readings appear after a payer demanding RWE the protocol cannot generate.
• Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the page RWE can replace or turns on in RWE protocol that may not meet regulator expectations.

Analysis required

• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a payer demanding RWE the protocol cannot generate.
• For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against a payer demanding RWE the protocol cannot generate and write the one fact that would move RWE can replace or for regulatory-affairs lead.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / FDA Response and Labeling packet (RWE protocol that may not meet regulator expectations after a payer demanding RWE the protocol cannot generate). The follow-on FDA Response and Labeling action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.